Jay Moorin

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA.

Acurian, Inc. provides clinical trial patient recruitment and retention solutions for the life sciences industry. It offers recruitment feasibility, site identification and selection, patient recruitment and retention services. The firm also provides the recruitment manager platform or database that features feasibility and project management capabilities. The company was founded by Lance D. Converse, David Restrepo and Leslie D. Michelson in 1998 and is headquartered in Horsham, PA.

Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

ACMI Corp. used to design, manufacture and market medical devices. Its products were diagnostic & therapeutic endoscopic instrumentation products. The company was founded in 1908 by Reinhold Wappler and was headquartered in Southborough, MA.

Part of Baxter International, Inc., Epic Therapeutics, Inc. is a company that develops therapeutic products used as injections or inhalation. The company is based in Norwood, MA. Epic Therapeutics was acquired by Baxter Healthcare Corp. on November 11, 2002.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA.

Aires Pharmaceuticals, Inc. develops drugs to treat pulmonary disorders. It offers Aironite, an inhaled drug that is used to treat adult and pediatric pulmonary hypertension, cystic fibrosis, pneumonia and other respiratory infections. The company was founded by Wendy S. Johnson in 2006 and is headquartered in San Diego, CA.

Pegasi Energy Resources Corp. is an organic growth-oriented independent energy company, which engages in the exploration, development, and production of oil and natural gas. It currently holds interest in properties located in Cass and Marion Counties, Texas, home to the Rodessa oil field. The company was founded in March 2007 and is headquartered in Dallas, TX.